Patterns of Neurodevelopmental Disorders
Launched by RICHARD FRYE · Jan 16, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The "Patterns of Neurodevelopmental Disorders" clinical trial is designed to study various conditions that affect brain development, including Autism Spectrum Disorder, Down Syndrome, and Epilepsy, among others. The goal of this research is to carefully look at the results of medical tests to find common patterns in symptoms and possible causes of these disorders. This could help improve understanding and treatment options for affected individuals.
To participate in this study, you or your child should be experiencing developmental delays and have had a clinical visit at the Rossignol Medical Center. The trial is open to individuals of all ages and genders. If you join, you can expect to undergo a series of evaluations and tests that will help researchers gather important information about these disorders. By participating, you could help pave the way for better insights into neurodevelopmental disorders, which might benefit many families in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Neurodevelopmental delays Clinical visit at an Rossignol Medical Center
- Exclusion Criteria:
- • -
About Richard Frye
Richard Frye is a distinguished clinical trial sponsor known for his commitment to advancing medical research and enhancing patient care. With extensive expertise in neuroscience and pediatric neurology, he leads innovative studies aimed at understanding and treating complex neurological conditions. His focus on collaborative research efforts fosters interdisciplinary approaches, ensuring that trials are designed to meet the highest scientific and ethical standards. Through his leadership, Richard Frye aims to bridge the gap between research and clinical practice, ultimately improving therapeutic outcomes for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Phoenix, Arizona, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported